Johnson & Johnson plans to begin what would be the largest, late-stage trial testing for a potential COVID-19 vaccine in September.
According to the U.S. pharmaceutical company Thursday, the phase three trial will enroll up to 60-thousand healthy people over 18 years old, across nearly 180 locations in the U.S., as well as other countries.
Participants will be randomly selected to receive a dose of the potential vaccine or a placebo, which will determine whether the vaccine is both safe and effective.
The company added that the participants will be followed by researchers for more than two years.
Johnson & Johnson expects possible vaccine batches for potential emergency use to be available in early 2021.